Then Applied Biosystems (ABI) introduced its next-generation sequencing machine, which was quickly followed by instruments from Illumina and Roche 454. Throughput per machine increased 500,000 ...

Next-generation DNA sequencing has started a revolution in genomics and created the opportunity for large-scale sequencing projects, such as the recently announced 1,000 Genomes Project—an ...

What is next-generation sequencing? Next-generation sequencing (often noted as NGS), describes the high-throughput technologies that can now determine the sequence of a given nucleic acid strand, such ...

This Special Series from JCO Precision Oncology and JCO Clinical Cancer Informatics includes reviews addressing the challenge of structuring nomenclature for Next Generation Sequencing (NGS) that is ...

This image illustrates the typical steps in next-generation sequencing (excluding single-molecule sequencing methods). The process begins with isolating genomic DNA (a) and breaking it into short ...

The MiSeq desktop sequencer offers low throughput flowcells and long read lengths. It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The ...

The Bristol Genomics Facility has the capacity to run both high output and low output next generation sequencing experiments. The Illumina NextSeq500 system is perfect for the sequencing of whole ...

Market Growth Driven by Advancements in Genomic Research, Rising Demand for Personalized Medicine, and Key Applications in ...

The Genomics Core now has an Illumina NextSeq500 Next Generation Sequencing (NGS) instrument! This will expand our capacity of services already offered for NGS. Feel free to call or email us to find ...

One of UMass Lowell’s Core Research Facilities, the Next Generation Sequencing & Genomics Lab provides Next-Generation DNA & RNA sequencing services and technical expertise including NGS library prep, ...

由于种种原因，NEXT即将关站，感谢大家5年来对NEXT的关注与热爱。 在没有NEXT的日子里，如果您想继续获取最新产品信息，也可以继续关注36氪。

和黄医药首席执行官兼首席科学官苏慰国博士表示："现在，武田已在日本取得 FRUZAQLA®批准，这证明了我们全球数据包的实力以及这种新药为转移性结直肠癌患者提供急需的治疗选择的潜力。在过去的十几年来，武田一直是日本的转移性结直肠癌治疗领域的领导者，我们有信心武田能够将FRUZAQLA®带向日本患者。" ...